Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,245.25 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹230.77B
Enterprise Value₹224.58B
Total Cash (Recent Filing)₹13.02B
Total Debt (Recent Filing)₹2.55B
Price to Earnings (P/E)68.4
Beta0.60
Next Earnings
Apr 30, 2026EPS Estimate
7.44Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.70
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,577.00Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)35.55
Revenue Forecast (FY)₹30.60B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained gross margin (~60.8%) and near-20% net margin indicate durable pricing power and efficient lab operations. Healthy EBIT/EBITDA margins imply the business converts volumes into cash profitably, supporting reinvestment in network expansion and long-term margin maintenance.
Strong Cash GenerationConsistent operating cash flow and growing free cash flow provide durable funding for capex, working capital and strategic initiatives without reliance on external debt. This cash strength supports organic growth, potential M&A, and financial resilience through industry cycles.
Conservative Balance SheetA low leverage profile and strong equity base offer long-term financial flexibility to expand labs, absorb shocks, and fund programs. Conservative capital structure reduces refinancing risk and preserves ability to invest in diagnostics infrastructure as the network scales.
Bears Say
ROE Improvement NeededA noted need to improve ROE suggests the company could be underutilizing equity capital or facing limits in translating asset base into higher shareholder returns. Over months this could pressure investor expectations unless management boosts asset turns, margins or capital efficiency.
Moderate Revenue Growth RateMid-teens single-digit revenue growth (~10.8%) is respectable but modest for a network-driven diagnostics player. Over 2–6 months this pace may constrain market share gains and limit operating-leverage upside unless offset by geographic expansion, higher-value tests, or faster referral growth.
Pricing & Contract ExposureHeavy reliance on fee-for-service and negotiated B2B contracts creates structural exposure to pricing pressure from hospitals, insurers or corporates. Durable margin risk exists if payers or large clients press rates or if routine tests become commoditized, limiting long-term margin expansion.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1245.25 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹230.77B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Apr 30, 2026 which is in 21 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.7 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹0.925.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Undervalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.44.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.7 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
LALPATHLAB Stock 12 Month Forecast
Average Price Target
₹1,577.00
▲(7.06% Upside)
Technical Analysis
Jupiter Life Line Hospitals Ltd.
―
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―